Exchange Traded Concepts LLC Has $11.67 Million Stock Holdings in BWX Technologies, Inc. $BWXT

Exchange Traded Concepts LLC grew its stake in shares of BWX Technologies, Inc. (NYSE:BWXT) by 44.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,285 shares of the technology company’s stock after purchasing an additional 19,508 shares during the period. Exchange Traded Concepts LLC owned about 0.07% of BWX Technologies worth $11,668,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Northern Trust Corp raised its holdings in BWX Technologies by 2.2% during the 1st quarter. Northern Trust Corp now owns 832,615 shares of the technology company’s stock worth $82,137,000 after buying an additional 17,526 shares during the period. Martingale Asset Management L P increased its position in shares of BWX Technologies by 267.5% in the first quarter. Martingale Asset Management L P now owns 10,308 shares of the technology company’s stock worth $1,017,000 after acquiring an additional 7,503 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of BWX Technologies by 142.5% in the first quarter. Ameriprise Financial Inc. now owns 421,646 shares of the technology company’s stock worth $41,595,000 after acquiring an additional 247,795 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of BWX Technologies by 42.1% during the first quarter. AlphaQuest LLC now owns 7,485 shares of the technology company’s stock valued at $738,000 after acquiring an additional 2,217 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of BWX Technologies by 56.1% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 2,339 shares of the technology company’s stock valued at $231,000 after acquiring an additional 841 shares in the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Truist Financial lifted their price objective on shares of BWX Technologies from $173.00 to $200.00 and gave the stock a “hold” rating in a research report on Tuesday, November 4th. Bank of America raised their target price on BWX Technologies from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen raised BWX Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Northland Securities set a $225.00 price objective on BWX Technologies in a research note on Tuesday, November 4th. Finally, Zacks Research cut BWX Technologies from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, BWX Technologies has a consensus rating of “Moderate Buy” and an average target price of $196.23.

Insider Buying and Selling

In other BWX Technologies news, CEO Rex D. Geveden sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $197.90, for a total value of $1,979,000.00. Following the completion of the sale, the chief executive officer directly owned 187,594 shares of the company’s stock, valued at $37,124,852.60. The trade was a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.47% of the stock is owned by corporate insiders.

BWX Technologies Price Performance

BWXT opened at $178.32 on Tuesday. The stock has a market cap of $16.30 billion, a price-to-earnings ratio of 53.55, a PEG ratio of 3.45 and a beta of 0.86. BWX Technologies, Inc. has a 1 year low of $84.21 and a 1 year high of $218.50. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 1.21. The stock has a fifty day moving average price of $188.14 and a 200 day moving average price of $169.76.

BWX Technologies (NYSE:BWXT) last issued its earnings results on Monday, November 3rd. The technology company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.15. BWX Technologies had a return on equity of 30.70% and a net margin of 10.04%.The company had revenue of $866.29 million for the quarter, compared to analyst estimates of $795.48 million. During the same period in the prior year, the firm posted $0.83 EPS. The business’s revenue was up 28.9% compared to the same quarter last year. BWX Technologies has set its FY 2025 guidance at 3.750-3.800 EPS. Analysts forecast that BWX Technologies, Inc. will post 3.23 EPS for the current fiscal year.

BWX Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Wednesday, November 19th were paid a $0.25 dividend. The ex-dividend date was Wednesday, November 19th. This represents a $1.00 dividend on an annualized basis and a yield of 0.6%. BWX Technologies’s payout ratio is 30.03%.

About BWX Technologies

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.